Prosecution Insights
Prosecution Insights
54 pending office actions • 26 art units • 51 examiners • 0 of 54 (0%) have an AI response strategy ready • 81 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 20 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 20 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (6%) |
| §101 + other | 2 (4%) |
| §103 only | 12 (22%) |
| §102 only | 3 (6%) |
| §112 only | 8 (15%) |
| Double-patenting only | 5 (9%) |
| Double-patenting + other | 5 (9%) |
| Multi-statute (no §101) | 15 (28%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, SEONG JONG | 2 | 100.0% | +0.0% |
| AEDER, SEAN E | 2 | 56.9% | +19.9% |
| MAHLUM, JONATHAN DAVIS | 2 | 51.5% | +20.8% |
| GAUGER, PAUL RANDALL | 1 | 57.1% | -7.9% |
| NGUYEN, TRAN N | 1 | 61.9% | +16.9% |
| KRASNOW, NICHOLAS R | 1 | 66.5% | +12.5% |
| HARANDI, SIAMAK | 1 | 90.8% | +7.4% |
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| JACKSON, SHAWQUIA | 1 | 77.9% | -3.3% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18918033 | FRAMEWORK FOR DOCUMENT LAYOUT AND INFORMATION EXTRACTION | HARANDI, SIAMAK | — |
| 18389891 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | KIM, SEONG JONG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011884 | TREATING RHEUMATOID ARTHRITIS | HOWARD, ZACHARY C | 32d overdue |
| 17905870 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | KAUFMAN, CLAIRE M | 30d overdue |
| 18539519 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KIM, SEONG JONG | 9d overdue |
| 18152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | STOICA, ELLY GERALD | 3d overdue |
| 17798983 | ANTI-BCMA THERAPY IN AUTOIMMUNE DISORDERS | EDGINGTONGIORDANO, FRANCESCA | 3d overdue |
| 18043562 | LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA | BERHANE, SELAM | 70d |
| 18986183 | Leveraging Large Language Models for Automating Lines of Therapy Adjudication in Cancer Patients | NGUYEN, TRAN N | — |
| 18693731 | METHODS OF CONTROLLING THE LEVEL OF DISSOLVED OXYGEN (DO) IN A SOLUTION COMPRISING A RECOMBINANT PROTEIN IN A STORAGE CONTAINER | KIPOUROS, HOLLY MICHAELA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785585 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | MAHLUM, JONATHAN DAVIS | 132d overdue |
| 18463743 | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS | AEDER, SEAN E | 44d overdue |
| 17763614 | COMPOSITE BIOMARKER FOR CANCER THERAPY | AEDER, SEAN E | 11d overdue |
| 18986183 | Leveraging Large Language Models for Automating Lines of Therapy Adjudication in Cancer Patients | NGUYEN, TRAN N | — |
| 18857946 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | KRASNOW, NICHOLAS R | — |
| 18908888 | CRYSTALLINE FORMS OF A PAR4 INHIBITOR | KIFLE, BRUCK | — |
| 18839055 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | VALENROD, YEVGENY | — |
| 17773425 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | MAHLUM, JONATHAN DAVIS | — |
| Art Unit | Apps |
|---|---|
| 1625 | 4 |
| 1621 | 4 |
| 1642 | 4 |
| 1629 | 3 |
| 1691 | 2 |
| 1622 | 2 |
| 1647 | 2 |
| 1626 | 2 |
| 1641 | 2 |
| 1674 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19574713 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | GAUGER, PAUL RANDALL | 1629 | DP | Non-Final OA | — | Pending | Mar 23, 2026 |
| 18986183 | Leveraging Large Language Models for Automating Lines of Therapy Adjudication in Cancer Patients | NGUYEN, TRAN N | — | §101 | Non-Final OA | — | Pending | Dec 18, 2024 |
| 18857946 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | KRASNOW, NICHOLAS R | 1744 | §103 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18918033 | FRAMEWORK FOR DOCUMENT LAYOUT AND INFORMATION EXTRACTION | HARANDI, SIAMAK | — | DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18908888 | CRYSTALLINE FORMS OF A PAR4 INHIBITOR | KIFLE, BRUCK | — | DP | Non-Final OA | — | Pending | Oct 08, 2024 |
| 18839079 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | JACKSON, SHAWQUIA | — | §112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18839055 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | VALENROD, YEVGENY | — | §112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18769916 | BIARYL KINASE INHIBITORS | SHIM, DAVID M. | — | §103Other | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18718484 | BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS | JEAN-LOUIS, SAMIRA JM | — | §112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18694424 | METHODS OF TREATING HAIR-LOSS DISORDERS WITH TYK2 INHIBITORS | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18693731 | METHODS OF CONTROLLING THE LEVEL OF DISSOLVED OXYGEN (DO) IN A SOLUTION COMPRISING A RECOMBINANT PROTEIN IN A STORAGE CONTAINER | KIPOUROS, HOLLY MICHAELA | — | §102§103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18684747 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3- (1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE | CHANDRAKUMAR, NIZAL S | 1625 | §103DP | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18294609 | CELL CULTURE METHODS FOR PRODUCING THERAPEUTIC PROTEINS | METCALF, MATTHEW CURRAN | — | §103 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18413928 | MODIFIED SELF-IMMOLATING MOIETIES FOR USE IN PRODRUGS AND CONJUGATES AND METHODS OF USING AND MAKING | BOWLES, DAVID PAUL | — | DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18394005 | LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASE | TOWNSLEY, SARA ELIZABETH | 1629 | §101§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18393940 | LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASE | RAO, SAVITHA M | 1691 | §101§103§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18389891 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | KIM, SEONG JONG | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18539519 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KIM, SEONG JONG | 1621 | §103§112Other | Non-Final OA | 9d overdue | Pending | Dec 14, 2023 |
| 18531312 | USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS | MOSELEY II, NELSON B | — | §102§103Other | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18526197 | Line of Therapy Identification from Clinical Documents | SOREY, ROBERT A | 3682 | §101 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18560520 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NEAGU, IRINA | 1629 | §103Other | Non-Final OA | 31d overdue | Pending | Nov 13, 2023 |
| 18504198 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | AULAKH, CHARANJIT | 1621 | §102§103§112Other | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18559006 | METHODS OF IN VITRO DISSOLUTION | MUTREJA, JYOTI NAGPAUL | 1798 | §102§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18284531 | CRYSTAL FORMS OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE | CHAO, ALLEN | 1622 | §102 | Non-Final OA | 26d overdue | Pending | Sep 27, 2023 |
| 18367252 | ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF | SUNSHINE, HANNAH LOUISE | 1647 | Other | Non-Final OA | 29d | Pending | Sep 12, 2023 |
| 18463743 | TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS | AEDER, SEAN E | 1642 | §103Other | Non-Final OA | 44d overdue | Pending | Sep 08, 2023 |
| 18547751 | PATIENT RESPONSE-BASED BIOMARKER TOPOLOGY QUANTIFICATION AND ASSESSMENT FOR MULTIPLE TISSUE TYPES | FITZPATRICK, ATIBA O | 2677 | §101 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18450847 | KRAS INHIBITORS | STOCKTON, LAURA LYNNE | 1626 | §102§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18450219 | METHOD OF TREATING LUNG CANCER | GANGLE, BRIAN J | 1645 | §112DP | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18336889 | COMPOSITIONS COMPRISING AN ANTI-LAG-3 ANTIBODY OR AN ANTI-LAG-3 ANTIBODY AND AN ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | KIM, YUNSOO | 1641 | §112 | Final Rejection | 19d overdue | Pending | Jun 16, 2023 |
| 18331831 | KRAS INHIBITORS | COUGHLIN, MATTHEW P | 1626 | §102§103§112 | Final Rejection | — | Pending | Jun 08, 2023 |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | WELLS, LAUREN QUINLAN | 1622 | §103 | Final Rejection | 26d overdue | Pending | Mar 16, 2023 |
| 18043562 | LAG-3 ANTAGONIST THERAPY FOR HEPATOCELLULAR CARCINOMA | BERHANE, SELAM | 1675 | §102§112 | Non-Final OA | 70d | Pending | Feb 28, 2023 |
| 18042018 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | MOU, LIYUAN | 1628 | §102§103DP | Final Rejection | 111d overdue | Pending | Feb 17, 2023 |
| 18166881 | Clinical Outcome Prediction By Application Of Machine Learning Models To Clinical Data | HEIN, DEVIN C | 3686 | §103 | Final Rejection | — | Pending | Feb 09, 2023 |
| 18152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | STOICA, ELLY GERALD | 1647 | §103§112 | Non-Final OA | 3d overdue | Pending | Jan 09, 2023 |
| 18011884 | TREATING RHEUMATOID ARTHRITIS | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | 32d overdue | Pending | Dec 21, 2022 |
| 17998521 | DOSING AND ADMINISTRATION OF ACTIVATABLE ANTI-CTLA-4 ANTIBODY | PETERS, ALEC JON | 1641 | DP | Final Rejection | 3d overdue | Pending | Nov 11, 2022 |
| 17915593 | AUTOMATED SYSTEM AND METHOD FOR ANALYZING SAMPLES FROM A BIOREACTOR | NGUYEN, HENRY H | 1758 | §103§112 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17905870 | ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY | KAUFMAN, CLAIRE M | 1674 | §103§112 | Non-Final OA | 30d overdue | Pending | Sep 08, 2022 |
| 17798983 | ANTI-BCMA THERAPY IN AUTOIMMUNE DISORDERS | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§103 | Non-Final OA | 3d overdue | Pending | Aug 11, 2022 |
| 17786442 | COMBINATIONS OF DGK INHIBITORS AND CHECKPOINT ANTAGONISTS | LU, CHENG | 1642 | §112Other | Final Rejection | 54d | Pending | Jun 16, 2022 |
| 17786239 | SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS | SAMSELL, RILLA MARIE | 1624 | §112 | Non-Final OA | 132d overdue | Pending | Jun 16, 2022 |
| 17785585 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | MAHLUM, JONATHAN DAVIS | 1625 | §112 | Final Rejection | 132d overdue | Pending | Jun 15, 2022 |
| 17779104 | LABEL-FREE N-GLYCAN QUANTIFICATION METHODS | FRITCHMAN, REBECCA M | 1700 | §103 | Final Rejection | — | Pending | May 23, 2022 |
| 17773791 | COMBINATION THERAPY WITH ANTI-PVRIG ANTIBODIES FORMULATIONS AND ANTI-PD-1 ANTIBODIES | HALVORSON, MARK | 1646 | §103§112DP | Non-Final OA | — | Pending | May 02, 2022 |
| 17773425 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | MAHLUM, JONATHAN DAVIS | 1625 | §102§112 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17772865 | METHODS OF TREATMENT WITH ANTIBODIES AGAINST BCMA AND CD3 | LEE, YIE CHIA | 1642 | §103Other | Final Rejection | 78d | Pending | Apr 28, 2022 |
| 17763614 | COMPOSITE BIOMARKER FOR CANCER THERAPY | AEDER, SEAN E | 1642 | §103 | Final Rejection | 11d overdue | Pending | Mar 24, 2022 |
| 17760692 | DUAL CAPTURE METHOD FOR ANALYSIS OF ANTIBODY-DRUG CONJUGATES | IVICH, FERNANDO NMN | 1678 | §112 | Non-Final OA | 71d overdue | Pending | Mar 15, 2022 |
| 17753657 | PHARMACEUTICAL FORMULATIONS OF INDOLEAMINE 2, 3-DIOXYGENASE INHIBITORS | NGUYEN, NGOC-ANH THI | 1615 | §103 | Final Rejection | — | Pending | Mar 10, 2022 |
| 17639489 | EXTENDED RELEASE DOSAGE FORMS FOR TYK2 INHIBITORS | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103§112 | Final Rejection | — | Pending | Mar 01, 2022 |
| 17613904 | METHODS OF MONITORING CELL CULTURE MEDIA | SPANGLER, JOSEPH RANKIN | 1656 | §103 | Non-Final OA | — | Pending | Nov 23, 2021 |
| 17610634 | AGONISTS OF ROR GAMMAt | BELL, SARA ELIZABETH | 1625 | §102 | Non-Final OA | — | Pending | Nov 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial